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C-Reactive Protein (CRP) is a biomarker indicating tissue damage, inflammation, and
infection. High-sensitivity CRP (hsCRP) is an emerging biomarker often used to estimate
an individual’s risk for future coronary heart disease (CHD). hsCRP levels falling below
1.00 mg/l indicate a low risk for developing CHD, levels ranging between 1.00 mg/l and
3.00 mg/l indicate an elevated risk, and levels exceeding 3.00 mg/l indicate high risk.
Multiple Genome-Wide Association Studies (GWAS) have identified a number of genetic
polymorphisms which influence CRP levels. SNPs implicated in such studies have been
found in or near genes of interest including: CRP, APOE, APOC, IL-6, HNF1A, LEPR, and
GCKR. A strong positive correlation has also been found to exist between CRP levels and
BMI, a known risk factor for CHD and a state of chronic inflammation. We conducted a
series of analyses designed to identify loci which interact with BMI to influence CRP levels
in a subsample of European-Americans in the ARIC cohort. In a stratified GWA analysis,
15 genetic regions were identified as having significantly (p-value < 2.00*10-3) distinct
effects on hsCRP levels between the two obesity strata: lean (18.50 kg/m2 < BMI < 24.99
kg/m2) and obese (BMI ≥ 30.00 kg/m2). A GWA analysis performed on all individuals
combined (i.e. not a priori stratified for obesity status) with the inclusion of an additional
parameter for BMI by gene interaction, identified 11 regions which interact with BMI to
influence hsCRP levels. Two regions containing the genes GJA5 and GJA8 (on
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chromosome 1) and FBXO11 (on chromosome 2) were identified in both methods of
analysis suggesting that these genes possibly interact with BMI to influence hsCRP levels.
We speculate that atrial fibrillation (AF), age-related cataracts and the TGF-β pathway may
be the biological processes influenced by the interaction of GJA5, GJA8 and FBXO11,
respectively, with BMI to cause changes in hsCRP levels. Future studies should focus on
the influence of gene x bmi interaction on AF, age-related cataracts and TGF-β.
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CHAPTER 1: BACKGROUND AND LITERATURE REVIEW
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1.1 C-Reactive Protein
C-Reactive Protein Definition
C-Reactive Protein (CRP), which is named for its ability to “precipitate the somatic Cpolysaccharide of Streptococcus pneumonia” (1), is an acute-phase protein which is a
sensitive systemic marker indicating tissue damage, inflammation, infection and malignant
neoplasia. It has also been found to be a highly stable analyte and “immunoassays for it are
robust, well-standardized, reproducible, and readily available” (2). Because of these
characteristics, CRP has been the most effective laboratory measurement in organic disease
screening, monitoring inflammation response, detecting infection for individuals who are
immunocompromised and in identifying chronic inflammation. (1)
High-sensitivity CRP (hsCRP) is a nephelometric measurement with sensitivity down
to 0.04 mg/l (3), and is the measurement most often used to estimate an individual’s risk for
future coronary heart disease. The average hsCRP levels of middle-aged Americans fall
between 1.00 mg/l and 2.00 mg/l. A single hsCRP measurement above 10.00 mg/l is
probably an indication of acute infection. A repeated measurement (2-3 weeks after the
initial high measurement) of above 10.00 mg/l is evidence of more serious, underlying
inflammation (4). Level of hsCRP increase with age and obesity, have no diurnal or
seasonal variation, and are affected by liver failure (2). Interestingly, most individuals will
hold a consistent level of plasma hsCRP characteristic of their age and health. Two
measurements taken years apart have a self correlation coefficient of 0.5 (2).
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CRP Levels as a Response to Inflammation
Inflammation increases CRP synthesis in hepatocytes. CRP synthesis is controlled by
cytokines, primarily interleukin 6 (IL-6), originating at the site of inflammation. Values of
CRP can rise from less than .05 mg/l to over 5.00 mg/l within six hours. After 48 hours,
CRP levels may peak at up to 500.00 mg/l (a 10,000 fold increase) (2). After the
inflammation ceases, CRP levels drop quickly. Because the rate of degradation of CRP is
constant under all conditions (its half-life is 19 hours), its rate of synthesis determines its
circulating level and is a reflection of the stimulus intensity (5).

CRP Production
Following inflammation plasma CRP is synthesized in hepatocytes by the CRP gene
(located on the short arm of chromosome 1). This synthesis is transcriptionally regulated by
IL-6 and may be increased by the cytokine, interleukin-1β (IL-1β). Both IL-6 and IL-1β are
produced at the site of inflammation and activate transcription factors in the cytidinecytidine-adenosine-adenosine-thymidine-enhancer-binding-proteins (C/EBP) family,
C/EBPβ and C/EBPδ.

In the proximal promoter region of CRP, C/EBP binding sites

interact with binding sites for signal transducer and activator of transcription 3 (STAT3) and
Rel (proto-oncogene c-Rel) transcription factors. This interaction stabilizes binding of
C/EBPβ and C/EBPδ to the CRP promoter, maximizing CRP production (6).
Tumor necrosis factor α (TNF-α) (7) and transforming growth factor- β (TGF-β) (8)
may also help regulate CRP production. CRP production in other cells, such as neurons,
monocytes, and lymphocytes has also been reported. However, the mechanisms of
3

production are unknown, and it is thought that production in these cells does not affect
plasma CRP levels significantly (6).

1.2 Coronary Heart Disease

Coronary heart disease (CHD) is the leading cause of death for both men and women
in the United States and is caused by atherosclerosis (9). Atherosclerosis is characterized by
the accumulation of lipids and other substances (such as leukocytes and smooth muscle
cells) on the arterial walls (9, 10). This accumulation, called a plaque or fiberatheroma,
consists of a lipid core and fibrous cap (9, 10, 11, 12, 13). Leukocytes cause thinning of the
plaques’ fibrous cap by inhibiting collagen synthesis. The plaque may weaken and
eventually rupture, causing clotting of arterial blood and interrupting blood flow to the heart,
causing acute CHD or myocardial infarction (MI) (10, 14).

Coronary Heart Disease and Inflammation
Inflammation accompanies atherosclerosis. Leukocytes, mediators of inflammation
mediators, accumulate in early atherosclerotic lesions when the normal endothelial
monolayer of the arterial wall becomes inflamed. The cell surfaces express selective
adhesion molecules, such as vascular cell adhesion molecule-1 (VCAM-1) (10) and
endothelial leukocyte adhesion molecule-1 (ELAM) (14), which subsequently bind to
monocytes and T lymphocytes. Leukocytes migrate into the intima in a process called
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diapedesis (14). They also propagate an inflammatory response, including secretion of
cytokines (IL-6, TNF-α, and IL-1β) (14), which are believed to influence CRP
production(10). Because of this, CRP is used as a biomarker for the risk of CHD. Some
investigators (14, 15) believe that CRP plays a causal role in atherosclerosis and is not
simply a passive biomarker.

Coronary Heart Disease and CRP
In addition to atherosclerosis, CHD, and MI, elevated CRP levels have been associated
with type 2 diabetes, stroke, and mortality (16, 17, 18, 19, 20, 21). According to American
Heart Association (22), hsCRP levels below 1.00 mg/l indicate a low risk for CHD, levels
between 1.00 mg/l and 3.00 mg/l indicate an elevated risk, and levels exceeding 3.00 mg/l
indicate high risk. In one meta-analysis, it was shown that individuals with a baseline CRP
level in the upper tertile have a relative risk of 2.0 for CHD, compared to individuals in the
lowest tertile(20). Both men and women with CRP levels above 10.00 mg/l are 2 to 3 times
more likely to experience MI, peripheral artery disease, and ischemic stroke (20, 21, 23, 24.
Individuals with elevated CRP levels and unstable angina or MI are more likely to
experience cardiac complications (25, 26). It has also been suggested that the susceptibility
to coronary events of obese individuals may be attributable to the association of high plasma
CRP levels with increased Body Mass Index (BMI) (20).
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1.3 BMI and Obesity
Definition of Obesity
Obesity is defined by the World Health Organization (27)as having a BMI of over 30.00
kg/m2; a person with a BMI between 25 and 30 kg/m2 is considered overweight. A normal
weight, or lean, individual will have a BMI which falls between 18.50 and 24.99 kg/m2. In
2007 and 2008, the overall age-adjusted prevalence of obesity in the United States was
33.8% (32.3% in men, 35.5% in women) (28). The overall prevalence of those either
overweight or obese was 68.0%, 72.3% in men and 64.1% in women (28). In the past 30
years, the global prevalence of obesity has tripled (27, 29, 30). Around the world, one
billion adults and 155 million children are overweight, and 300 million adults and 40
million children are obese (27, 31). The causes of obesity are both environmental and
genetic in origin. Lack of physical activity and consumption of energy-dense foods with
high saturated fat content are two of the major environmental factors influencing obesity
(27). Smoking, alcohol consumption, and depression have also been suggested as causal
factors (32, 33)
2
Obesity and CRP
A strong positive correlation exists between CRP levels and BMI (and other measures of
obesity, including waist-to-hip ratio (20) and those used to estimate visceral adiposity (26)).
This correlation could not be explained by other diseases or conditions known to increase
CRP levels (34). When a person is obese, they are considered to be in a state of low-grade,
chronic inflammation, marked by high CRP levels (7, 35).

In obese individuals, elevated
6

CRP is caused by adipokines, chemokines, and cytokines secreted by adipocytes (36).
Elevated cytokine levels, including IL-6 and TNF-α levels, have been observed in both
obese adults and obese children (7), and it is estimated that 25% of systemic IL-6 is released
into the circulation by adipose tissue (34). This means that in addition to being a state of
inflammation, obesity may also be also a promoter of inflammation and is a potential
mediator in the inflammatory process of coronary heart disease.

1.4 Genetics of CRP
Heritability
CRP heritability (the percentage of variation in CRP levels due to genetic variation) is
approximately 0.3 – 0.4 in multiple populations, including Caucasian Americans, Caucasian
Europeans, Japanese Americans, and Native Americans (37). A weakness of most
heritability studies is that they typically assume pure additivity among genes and among
genes and the environment. This thesis will investigate whether interactions between genes
and obesity influence CRP levels.
Heritability estimates indicate that genes affect a trait, but they do not identify
individual genes. Genome-Wide Association Studies (GWAS) have been used to identify
single nucleotide polymorphisms (SNPs) associated with CRP levels and their
corresponding genes. Table 1 is a list of SNPs associated with CRP in published genomewide association studies (38).
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Initial
Population
66,185
Individuals of
European
ancestry

Replication
Population
16,540
Individuals of
European
ancestry

10,112
Japanese
Individuals

2,742
Japanese
Individuals

17,967
European and
Indian Asian
men and
women

17,967
European and
Indian Asian
men and
women

SNP – risk
allele
rs4420638-A
rs2794520-C
rs1183910-G
rs4420065-C
rs4129267-C
rs1260326-T
rs6734238-G
rs12239046-C
rs9987289-A
rs10521222-C
rs10745954-A
rs12037222-A
rs1800961-C
rs340029-T
rs13233571-C
rs4705952-G
rs2847281-A
rs6901250-A
rs2836878-G
rs4903031-G
rs3093059-G
rs2097677-A
rs7310409-G
rs4420638-A

P-Value

Reference

9 x 10-139
2 x 10-186
2 x 10-124
4 x 10-62
2 x 10-48
5 x 10-40
2 x 10-17
1 x 10-15
3 x 10-13
9 x 10-13
2 x 10-11
6 x 10-11
2 x 10-9
4 x 10-9
4 x 10-9
1 x 10-8
2 x 10-8
5 x 10-8
2 x 10-7
5 x 10-6
4 x 10-21
4 x 10-11
3 x 10-8
3 x 10-7

39

rs7553007-A
rs1183910-T
rs4420638-G

8 x 10-44
1 x 10-30
5 x 10-27

41

1q21.3
1p31.3

Reported
Gene(s)
APOC1
CRP
HNF1A
LEPR
IL6R
GCKR
IL1F10
NLRP3
PPP1R3B
SALL1
ASCL1
PABPC4
HNF4A
RORA
BCL7B
IRF1
PTPN2
GPRC6A
PSMG1
RGS6
CRP
IL6
HNF1A
APOE-CICII-cluster
CRP
HNF1A
APOE,
APOC1,
APOCII
IL6R
LEPR

rs4537545-T
rs6700896-T

2 x 10-14
3 x 10-14

Region
19q13.32
1q23.2
12q24.31
1p31.3
1q21.3
2p23.3
2q13
1q44
8p23.1
16q12.1
12q23.2
1p34.3
20q13.12
15q22.2
7q11.23
5q31.1
18p11.21
6q22.1
21q22.2
14q24.2
1q23.2
7p15.3
12q24.31
19q13.32
1q23.2
12q24.31
19q13.32

40

909
individuals

5,106
individuals

12q24.31
19q13.32
1q23.2

HNF1A
APOE
CRP

rs1169310-A
rs2075650-?
rs11265260-?

2 x 10-8
1 x 10-7
7 x 10-6

42

6,345 women

NR

1q23.2
1p31.3
19q13.32
12q24.31
2p23.3
12q23.2
1q21.3

CRP
LEPR
APOE
HNF1A
GCKR
Unknown
IL6R

rs3091244-?
rs1892534-A
rs769449-?
rs7310409-A
rs780094-A
rs10778213-G
rs8192284-?

6 x 10-28
7 x 10-21
9 x 10-21
7 x 10-17
7 x 10-15
1 x 10-10
2 x 10-8

43

Table 1: Genes associated with CRP in Published Genome-Wide Association Studies
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CRP Gene
The most frequently studied gene in relation to CRP levels is the CRP gene itself, on
chromosome 1q21-23. Variants in this gene have been found in multiple GWA and
candidate gene studies to be associated with CRP levels (39, 40, 41, 42, 43, 36, 35, 44, 45).
One GWA study found that 3.4% of residual variation in CRP levels could be attributed to
the CRP gene (43). In another GWAS, rs7553007 in the CRP gene was the single
nucleotide polymorphism (SNP) found to be most associated with CRP (each minor allele
lowered CRP levels by 21%) (41). Bochud et al. also reported CRP to be influenced by
rs7553007 which tags multiple SNPs in the CRP gene. In women only, this SNP was also
positively associated with BMI, waist circumference, and fat mass (35).

IL-6 Gene
The IL6 gene on chromosome 7p15 has been studied in relation to CRP levels. A SNP
in the IL6 promoter region, rs2097677, was significantly associated with CRP levels in a Japanese
population (40). Five GWA studies have found variants in IL-6 to be associated with CRP

levels (39, 40, 41, 42, 43). One study (43) found the contribution of IL-6 to variation in
CRP levels to be 0.6%. A G-C transversion at -174, 5’ to IL6, has been inversely associated with
CRP levels (44).
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HNF1A Gene
Hepatocyte nuclear factor 1 homeobox A (HNF1A), located on chromosome
12q24.31, was reported in the five GWA studies to be significantly associated with CRP
levels. In addition to IL-6, nuclear factor kappa-light-chain-enhancer of activated B cells
(NF-κB), is involved in transcriptional control of CRP synthesis. NF-κB binding sites
interact with HNF-1α binding sites in the CRP gene promoter to help regulate CRP
synthesis. One GWAS (42) found five SNPs in HNF1A to be associated with CRP levels
including two nonsynonymous coding SNPs, rs1169288 and rs2464196. The strongest
significantly associated SNP, however, was rs1139310 in the HNF1A 3’ untranslated
region. Addition of each copy of the minor allele of this SNP was associated with “0.13
mg/l lower mean log(CRP) levels” (42). A common haplotype (frequency = 30%)
consisting of the minor alleles of rs1169288, rs1169286, rs2464196, and rs1169310 was
also found to be associated with lower CRP levels. Ridker et al. found 8 SNPS in HNF1A
to be significantly associated with CRP levels, and that 1.1% of residual variation in CRP
levels could be attributed to these polymorphisms.

APOE and LEPR Genes
Genes that have been previously found to be associated with obesity and
atherosclerosis is of particular interest in CRP GWA studies because of CRP’s known
association with BMI, waist circumference and adiposity. Such polymorphisms are
contained in the apolipoprotein E gene (APOE) (Lange) and the leptin receptor gene (LEPR)
(35). APOE, in addition to being involved in obesity, also plays a role in coronary heart
10

disease development. Its roles include “macrophage cholesterol efflux, platelet aggregation,
and allele-specific antioxidant and immune activities” (46, 47, 48). APOE was significantly
associated with CRP levels in 4 GWA studies (40, 41, 42, 43). Ridker and colleagues and
Reiner and colleagues. both found two variants at 19q13.32 near the APOE gene to be
associated with CRP (42, 43); 1.5% of variation in CRP levels was attributable to APOE
variants (43). Ridker et al. also noted that “two highly significant SNPs near the APOE
locus are in a block that includes APOC1 [apolipoprotein C1 gene] and TOMM40
[Translocase of outer mitochondrial membrane 40 homolog] loci” (43). Three GWA studies
found LEPR to be associated with CRP levels (35, 43, 49, 39, 41). Ridker et al. estimated
that 1.6% of variation in CRP levels was due to nine variants at the LEPR locus (1q31.3)
(43). CRP expression is induced by leptin receptor activation in vascular endothelial cells
(50). These data indicate that leptin may be a mediating factor in the relationship between
CRP and BMI/adiposity. One GWAS found a significant interaction ( p < 2.9x10-6) between
the LEPR gene and BMI that was associated with CRP levels.

GCKR
Two GWA studies (39, 43) found CPR levels to be associated with variants in the
glucokinase (hexokinase 4) regulator (GCKR) at chromosome 2p23.2, which is expressed in
hepatocytes. Ridker et al. estimated that 1.1% of variation in CRP levels is due to the SNPs
in the GCKR gene. The GCKR gene codes for a regulatory protein which inhibits
glucokinase in liver cells, possibly resulting in limited accumulation of glucose as glycogen
in hepatocytes (43).
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CHAPTER 2: RESEARCH DESIGN AND METHODS

12

2.1 Significance of Research
Obesity phenotypes (such as BMI) may interact with genes to increase a person’s risk
for many life-threatening diseases. Such diseases include atherosclerosis, CHD, type 2
diabetes, hypertension, and stroke (27). Obesity is also known to be associated with high
plasma CRP levels (which may be an additional risk factor for cardiovascular disease).
Defining the interaction between obesity and genes that affect CRP levels will help in better
characterizing risk factors for the aforementioned diseases.

2.2 Hypothesis and Specific Aims
The main hypothesis of this thesis is that BMI interacts with genetic variation to
influence CRP levels. This hypothesis will be tested by performing genome-wide
association analyses on data from the Atherosclerosis Risk in Communities (ARIC) study.
Aim 1: Investigate whether body mass index interacts with genes in a GWA study to
influence C-reactive protein levels in European-Americans.
Exploratory Aim 2: Compare and contrast two different statistical methods of analysis for
assessing gene x environment interaction used to investigate the previous aim.

13

2.3 Genome Wide Association Studies
Background
A genome wide association study (GWAS) is a hypothesis-free analysis which takes
between 300K and 1,000K SNPs into account. Many factors including the Human Genome
Project (2003), the international HapMap project, improved genotyping technologies, and
fast statistical genetic analysis technologies have all contributed significantly to the GWAS
movement in recent years.

In ARIC
Genotyping was performed in the ARIC study via the Affymetrix Genome-Wide
Human SNP Array 6.0 genotyping chip and quality control was performed (crucial because
of the huge amount of data in the study). Of those European Americans genotyped, 9,345
individuals remained after initial quality control exclusions. Subjects were excluded if they
did not allow use of their DNA. Individuals with genotype success rates < 95% and those
with a greater percentage of heterozygous genotypes than anticipated were also removed
from the sample. Relatedness was assessed using estimated identity by decent (IBD), and
one suspected first-degree relative of an included individual was removed from the sample.
(The subject with less missing data was retained). Other individuals were excluded because
of suspected mixed/contaminated samples, problems with one DNA plate, mismatches
between sex estimated from genotype data and phenotypic sex, mismatches with 39
previously genotyped SNPs, and identification as a genetic outlier based on average identity
by state (IBS) statistics and principal components analysis.

SNPs were excluded based on
14

no chromosome location, being monomorphic, being out of Hardy-Weinburg Equilibrium
(HWE) (p-value < 10-5), having a minor allele frequency (MAF) < 1%, and having a call
rate < 95%. Out of the original 841,820 called SNPs, 669,450 made it past quality control
and were used for imputation. Autosomal SNPs were imputed from HapMap Phase II CEU
samples (consisting of Utah residents with ancestry from northern and western Europe),
using Mach v1.0.16 software. A total of 2,543,887 SNPs will be used in this analysis.

2.4 Data Analysis Methods
Subjects
The GWA analyses for this project will be done in European Americans from the
Atherosclerosis Risk in Communities (ARIC) study. The study, sponsored by the National
Heart, Lung and Blood Institute (NHLBI), seeks to investigate atherosclerotic diseases and
cardiovascular risk factors by race, gender, location and date. The initial cohort comprised
15,792 participants between the ages of 45 and 64 who were ascertained in 1987 from four
different communities in the US. Roughly 4,000 individuals were recruited from each
community. These communities included Forsyth County, NC; the city of Jackson, MS
(where only African American residents were sampled); the northwestern suburbs of
Minneapolis, MN; and Washington County, MD. Individuals in the cohort were examined
every three years from 1987 until 1998 and continue to have yearly telephone follow-ups.
Information from the initial exams included medical, social and demographic data. This
thesis will use information from the 4th examination year (1996-1998), in which hsCRP,
BMI, age, sex and genotype data were collected for 7,675 European American individuals.
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Summary statistics will be calculated including mean, standard deviation, and median.
Simple comparison statistics will be done using a student’s t-test.

Determining Significance Levels
Due to the large number of tests required to run a GWAS, by chance alone, as many as
50,000 SNPs out of 1,000,000 will be significant at the 0.05 level. For this reason, a method
such as Bonferroni’s correction or permutation must be used to determine a significant pvalue. It is typical to correct for 1,000,000 SNPs allowing for a nominal significance value
of 0.05/2,500,000 or 5 x 10-8 (51).

Aim 1: Method 1
The first method used to approach aim 1 will be a stratified analysis. Individuals will
be separated into two categories based on their BMI: obese and lean. Regardless of gender,
an individual with a BMI ≥ 30.00 kg/m2 will be placed in the obese group where as an
individual with a BMI ≥ 18.50 kg/m2 and less than 25.00 kg/m2 will be placed in the lean
group. The raw measurement of hsCRP will not be directly used, but will instead be natural
log transformed to normalize the data. Genome wide association analyses will be performed
in each group to identify genetic variations associated with ln(hsCRP). Each analysis will
be done adjusting for sex and age. An additive genetic model for the alleles at each locus
will be assumed.
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Because ln(hsCRP) is a quantitative trait, a linear regression model for this analysis will be
used.
ln(hsCRP) = μ + β1age + β2sex + β3SNP + ε
The output of the analysis will supply the minor allele, the minor allele frequency, the
number of individuals used in the analysis, the β value for each SNP, and the standard error
for each β value. Each β value is tested against the null hypothesis that β = 0 (or that hsCRP
levels do not change with genotype) using a chi squared test. A corresponding p-value will
be calculated for each test.
Once the analysis is complete in both categories of obesity, genetic variants with a
significant association with ln(hsCRP) (p-value less than 5.00*10-8) will be examined. To
ensure that SNPs with possible moderate effects on hsCRP are not disregarded, those with pvalues less than 10-5 will also be inspected. The significant SNPs in each category will be
separated into regions of 800 kilobases (kb) and the most significant SNP in each region will
be chosen as the index SNP.
The difference between the index SNPs significant in one or both categories will be
tested using the T-statistic:
(bo – bl) / √(seo2 + sel2 - 2*corr(bo,bl)*seo*sel)
where bo/l is the beta estimate for each SNP in the obese and lean groups, seo/l is the standard
error of the β estimates for each SNP in the obese and lean groups and corr(bo,bl) is the
correlation between the lean and obese β estimates for all SNPs in the GWA analysis.
Because of the large sample size, the t-statistic will be treated as a z-score. The p-value of
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significance will be determined by dividing 0.05 by the number of unique regions being
examined. This method will help identify those regions which have diverse effects on CRP
levels for individuals in different weight classes.

Aim 1: Method 2
In the second method used to approach aim 1, the genome wide association analysis
will be performed on all individuals combined (i.e. not a priori stratified for obesity status)
with the inclusion of an additional parameter for BMI by gene interaction. The linear
regression model for this analysis is:
ln(hsCRP) = μ + β1age + β2sex + β3BMI + β4SNP + β4SNPxBMI + ε
The output of the analysis for each SNP will provide a β-value of interaction and a
corresponding p-value. A p-value of less than 10-5 will be considered to be statistically
significant for this interaction analysis. The top SNPs will be separated into 800 kb regions
with the most significant SNP in each region being chosen as the index SNP. Regions for
which this interaction is significant can be considered to have an interactive effect with BMI
on CRP levels.

Aim 2
Exploratory Aim 2 will be a comparison of the previously described methods. This
comparison will identify which genetic regions are most likely to interact with BMI to
influence CRP levels in European-Americans. In general, an indication of this will be
18

consistent effects across the two methods. Top regions that are significantly different
between the two classes of obesity from the first method and those which show significant
interaction with BMI from the second method will be identified. If these regions interact
with BMI/obesity in the same direction (indicated by β values) then they can be considered
to have an interactive effect on BMI. In each of the regions identified by both methods,
genes near the index SNP or containing the index SNP will be considered as having possible
interactive effects with BMI on hsCRP levels in European-Americans. The investigation of
gene x BMI interactions using these methods are initial studies and results will need to be
replicated in subsequent genome wide association studies.
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CHAPTER 3: RESULTS
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3.1 Summary Statistics
Of the 15,792 participants examined at baseline in the ARIC cohort, 11,440 are selfreported European-Americans. Of these individuals, 9,345 were genotyped and provided
informed consent to use their genetic information. At the fourth examination, hsCRP levels
were measured in 7,675 of the 9,345 genotyped individuals. One or more of BMI, age and
sex were not reported in 12 of the 7,675 individuals with hsCRP levels. Table 2 contains
summary statistics from the fourth examination for the 7,663 individuals with information
including genotype, BMI, age, sex, and hsCRP levels.
The sample included 46.59% (n = 3,570) males and 53.41% (n = 4,093) females. The
participants’ ages ranged between 53 and 75 and the average age was 63.11 (SD = 5.63).
Underweight (BMI < 18.50 kg/m2) individuals made up 0.74% (n = 57) of the sample;
27.18% (n = 2,083) of the individuals were lean (18.50 kg/m2 ≤ BMI < 25.00 kg/m2);
40.61% (n = 3,112) of the individuals were overweight (25.00 kg/m2 ≤ BMI < 30.00 kg/m2);
and 31.46% (n = 2,411) of the individuals were obese (BMI ≥ 30.00 kg/m2). Mean BMI was
28.31 kg/m2 (n = 7,663) with the average for men being 28.45 kg/m2 and the average for
women being 28.18 kg/m2.
Levels of hsCRP ranged between 0.15 mg/l and 142.74 mg/l and the average level was
4.13 (SD = 6.24) mg/l. Individuals whose hsCRP levels fell below 1.00 mg/l made up
23.72%. The average BMI of these individuals (n = 1818) was 25.78 kg/m2 (SD = 3.90).
Individuals who had hsCRP levels between 1.00 mg/l and 3.00 mg/l made up 35.50% of the
sample (average BMI 28.00 kg/m2, SD = 4.55). Most individuals (40.98%), however, had
hsCRP levels above 3.00 mg/l. This group’s average BMI was 30.03 kg/m2 (SD = 5.88). A
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total of 479 individuals had hsCRP levels above 10.00 mg/l. These individuals had an
average BMI of 30.90 kg/m2 (SD = 5.68).
On average, men had a significantly lower hsCRP level (
than women (

3.33 mg/l, SD = 5.94)

4.83 mg/l, SD = 6.43) (p < 0.0001). Mean hsCRP levels increased with

BMI (Table 2). In all categories of BMI, mean hsCRP levels were above the average for
American middle-aged adults (between 1.00 mg/l and 2.00 mg/l) (4). This was to be
expected due to the age range of the cohort and the fact that CRP increases with age (2).
Only individuals in the underweight category had a mean hsCRP level (
4.45) between 1.00 mg/l and 3.00 mg/l. The means in the lean (
overweight (

3.85 mg/l, SD = 6.53) and obese (

2.11 mg/l, SD =

3.08 mg/l, SD = 5.70),

5.45 mg/l, SD = 6.15) categories

were all above 3.00 mg/l.
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Table 2: Exam Year 4 Summary Statistics
Frequencies and means of select exam year 4 variables in European-American participants
in the ARIC cohort who had been previously genotyped. Basic mean comparison statistics
are also provided.
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3.2 AIM 1: Method 1
Summary Statistics
Since the first series of analyses uses information from only lean and obese
individuals, summary statistics are provided for each group separately. There were 2,083
lean individuals with BMI values between 18.50 kg/m2 and 24.99 kg/m2. There were 2,411
obese individuals (BMI ≥ 30.00 kg/m2). Table 3 contains summary statistics for lean
individuals; Table 4 contains statistics for obese individuals.
The mean age in the lean sample was 63.15 years (SD = 5.72) while the mean age in
the obese sample was 62.73 years (SD = 5.47) (p = 0.0114). The lean individuals in the
sample had an average BMI of 22.87 (SD = 1.55) kg/m2 and the average BMI for obese
individuals was 34.41 (SD = 4.16) kg/m2 (p < 0.0001). Lean individuals had an average
hsCRP level of 3.06 (SD = 5.66) mg/l and obese individuals had an average level of 5.45
(SD = 6.15) mg/l (p < 0.0001).
In the lean group, the men (making up 35.67% of the sample) had a mean BMI (
23.31 kg/m2, SD = 1.37) that was significantly greater than that of the women in the group
(

22.63 kg/m2, SD = 1.60) (p < 0.0001). The men, however, had a significantly lower

mean hsCRP level (

2.41 mg/l, SD = 3.87) than the women (

3.45 mg/l, SD = 6.47)

(p < 0.0001).
The obese women (making up 46.12% of the sample) had a significantly greater
average BMI (35.14 kg/m2, SD = 4.55) than the obese men (33.54 kg/m2, SD = 3.46) (p <
0.0001). The women also had a significantly higher average hsCRP level (6.80 mg/l, SD =
6.80 mg/l) as compared to the level in men (3.88 mg/l, SD = 4.83) (p < 0.0001). Individuals
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with hsCRP levels falling below 1.00 mg/l made up 37.25% (n = 776) of the lean subsample
and only 9.87% (n = 238) of the obese sample. The percentage of individuals with hsCRP
levels between 1.00 mg/l and 3.00 mg/l (elevated CHD risk) was similar between the lean
group (33.75%, n = 703) and obese group (32.73%, n = 789). There was a very large
difference, however, in the percentages of lean (29.00%, n = 604) and obese (57.40%, n =
1384) individuals with hsCRP levels above 3.00 mg/l, indicating high CHD risk. In the lean
group, 82 individuals (3.94%) had hsCRP levels above 10.00 mg/l. A greater percentage
(9.50%, n = 22.9) of obese individuals were also in this category.

Table 3: Summary Statistics for Lean and Obese Individuals
Frequencies and means of select exam year 4 variables in lean and obese EuropeanAmerican participants in the ARIC cohort who had been previously genotyped. Basic mean
comparison statistics are also provided.
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Table 4: Summary Statistics for Lean and Obese Individuals by Sex and hsCRP Level
Frequencies and means of select exam year 4 variables in lean and obese EuropeanAmerican participants in the ARIC cohort who had been previously genotyped. These
statistics are stratified for each obesity category by sex and hsCRP level (separately). Basic
mean comparison statistics are also provided.
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Natural Log Transformation
Histograms were plotted for hsCRP levels in both the lean and obese subsamples to
investigate their distribution. Neither distribution was normal so the hsCRP level for each
individual was natural log transformed for use in the linear regression analyses. Figures 1
and 2 show the distributions before and after transformation for the lean and obese
subsamples respectively.

Figure 1: Lean Subsample Distribution of hsCRP Levels Before and After Natural Log
Transformation
Percent of individuals is on the y-axis and hsCRP or ln(hsCRP) levels are on the x-axis.

Figure 2: Obese Subsample Distribution of hsCRP Levels Before and After Natural
Log Transformation
Percent of individuals is on the y-axis and hsCRP or ln(hsCRP) levels are on the x-axis.
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GWA Results in Lean Individuals
This thesis first examined the association of 2,543,887 genotyped and imputed SNPs
with natural log transformed hsCRP levels using linear regression in 2,083 lean EuropeanAmericans (18.50 kg/m2 ≤ BMI < 25.00 kg/m2). An additive genetic model was assumed,
adjusted for age and sex. No SNP met the pre-determined genome-wide significant p-value
of 2.00*10-8 and only one (rs2272417, p = 2.67*10-8) had a p-value less than 10-7.
However, 145 SNPs reached moderate levels of significance (defined as p < 10-5)
(Supplementary Table 1). These 145 SNPs fell into 16 separate 800 kb regions across the
genome. The SNPs with the most significant p-values of association in each region were
selected as index SNPs. Table 5 contains information about these index SNPs.
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Table 5: Top Regions in Lean Individuals (Method 1)
Index SNPs from the top 16 genomic regions associated with hsCRP levels in European-American lean individuals. Only the most
significant SNP, rs2272417, met the pre-determined genome wide significance value of 5*10-8. SNPs with function listed as unknown
have nearby gene(s) reported. Those with function listed as intron have the gene they are in indicated with an (i) and any nearby gene
reported (if relevant). ** = found to be previously associated with CRP levels in a GWAS (31)
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The most significant SNP found to be associated with hsCRP levels in 2,083 lean
individuals was rs2272417. Its significant negative β value indicates that with addition of
each minor allele (C) hsCRP levels are lowered by 0.2026. This SNP is in the intraflagellar
transport 172 homolog (IFT172) gene and is also in a region (see Figure 1) containing the
GCKR gene which was reported in two previous GWAS to be associated with CRP levels
(31, 56). Out of the 145 SNPs with a p-value of less than 10-5, 51 are in the 800 kb region
flanking IFT172 and GCKR (on chromosome 2). Along with rs2272417, 8 other SNPs are
contained in IFT172. Eight SNPs in the region are found in the GCKR gene and 3 of these
have p-values of less than 3*10-7 (rs11681351, rs4425043, and rs2293571).
The top SNP in the second most hsCRP-associated region in lean individuals is
rs11265260 (p-value = 1.54*10-7). Figure 1 shows the region of association (on
chromosome 1), containing the CRP gene, with rs11265260 as the index SNP. The SNP
rs11265260 specifically has been previously reported and replicated in one previous CRP
GWAS (59. Reiner). With addition of each minor allele (A) at the rs11265260 locus,
hsCRP levels decrease, on average, by 0.36.
rs12463210 (p-value = 4.28*10-7) on chromosome 19 is in third most significant
region associated with hsCRP levels in lean individuals. This SNP and 11 others with pvalues < 10-6 are in the region (Figure 1) containing zinc finger nuclease 536 (ZNF536).
Each additional A allele causes hsCRP levels to decrease, on average, by 0.99.
The SNP rs4448101 on chromosome 6 is also associated with hsCRP levels in lean
individuals with a significance of 6.90*10-7. Each C allele leads to an average change in
hsCRP of -0.18. Two other SNPs, rs2613562 (p-value = 3.39*10-6) and rs2612565 (p-value
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= 3.50*10-6), met moderate levels of significance in the same region. The gene alphaendomannosidase (MANEA) is contained in this region (Figure 1).
The fifth most significant associated region in lean individuals contains the SNP
rs157582 (p-value = 7.59*10-7). Its significant positive β value indicates that each C allele
increases hsCRP levels by 0.31. Genes in the 800 kb region (Figure 1) surrounding the SNP
include TOMM40, APOE and APOC1. Two other SNPs in the region reached the moderate
significance level of 10-6 (rs4420628 and rs6857).
Figure 1 also shows plots of 11 regions containing moderately significant top SNPs (pvalues of 10-5 to 10-7). Three of these regions were found in chromosome 1 and one was
found in each of chromosomes 2, 3, 4, 6, 9, 10, 12, and 20. Gene found in these regions
include: ephrin type-A receptor 8 (EPHA8), integrin β1 (ITGB1), neuropilin 1 (NRP1),
protocadherin 7 (PCDH7), F-box protein 11 (FBXO11), forkhead box N2 (FOXN2), gap
junction protein α5/8 (GJA5 and GJA8), voltage-gated potassium channel subunit beta-1
(KCNAB1), DDRGK domain containing 1 (DDRGK1), solute carrier organic anion
transporter family member 1B1 (SLCO1B1), TGF-B2, regulator factor X 6 (RFX6),
prostaglandin reductase 1 (PTGR1), and zinc finger nuclease 483 (ZNF483).
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Figure 3: Plots of Top Regions in Lean Individuals

Regional plots of 16 loci showing moderate genome-wide significant association with hsCRP levels in European-American lean individuals. This plot
shows the top 4 regions (refer to table 5). Each region’s rank is at the bottom right corner of each plot. In each plot, the top SNP is designated by a
purple diamond. – log10 p-values are on the y-axis and SNP genomic positions are on the x-axis. Genes which flank the 800 kb regions are reported
under the x-axis. The estimated rates of recombination are marked in blue. Each SNP is colored to show linkage disequilibrium (LD) with the top SNP.
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Figure 1 continued: Regional plots of 16 loci showing moderate genome-wide significant association with hsCRP levels in European-American lean
individuals. This plot shows the 5th through 8th most significant regions (refer to table 5). Each region’s rank is at the bottom right corner of each plot. In each
plot, the top SNP is designated by a purple diamond. – log10 p-values are on the y-axis and SNP genomic positions are on the x-axis. Genes which flank the
800 kb regions are reported under the x-axis. The estimated rates of recombination are marked in blue. Each SNP is colored to show linkage disequilibrium
(LD) with the top SNP.
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Figure 1 continued: Regional plots of 16 loci showing moderate genome-wide significant association with hsCRP levels in European-American lean
individuals. This plot shows the 9th through 12th most significant regions (refer to table 5). Each region’s rank is at the bottom right corner of each plot. In
each plot, the top SNP is designated by a purple diamond. – log10 p-values are on the y-axis and SNP genomic positions are on the x-axis. Genes which
flank the 800 kb regions are reported under the x-axis. The estimated rates of recombination are marked in blue. Each SNP is colored to show linkage
disequilibrium (LD) with the top SNP.
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Figure 1 continued: Regional plots of 16 loci showing moderate genome-wide significant association with hsCRP levels in European-American lean
individuals. This plot shows the 13th through 16th most significant regions (refer to table 5). Each region’s rank is at the bottom right corner of each plot. In
each plot, the top SNP is designated by a purple diamond. – log10 p-values are on the y-axis and SNP genomic positions are on the x-axis. Genes which
flank the 800 kb regions are reported under the x-axis. The estimated rates of recombination are marked in blue. Each SNP is colored to show linkage
disequilibrium (LD) with the top SNP.
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GWA Results in Obese Individuals
Genome-wide linear regression was subsequently performed to investigate the
association of 2,543,887 genotyped and imputed SNPs with ln(hsCRP) in 2,411 obese (BMI
≥ 30.00 kg/m2) European-Americans. Just as in the lean group, the analysis was adjusted for
age and sex and an additive genetic model was assumed. Significant or suggestive
association was observed in only 36 SNPs (p-value < 10-5) (see supplementary table 2). The
top 4 most significantly associated SNPs all fell into the same region on chromosome 19
flanking the genes TOMM40, APOE, and APOC. Two of these polymorphisms, rs4420638
(p-value = 1.86*10-9) and rs6857 (p-value = 1.31*10-8), reached the pre-determined genomewide significance level of 2.00*10-8. The 5th most associated SNP (rs12068753, p-value =
8.07*10-7) was located on chromosome 1 in a region containing the CRP gene. These SNPs
and the 31 others reaching suggestive significance levels were grouped into 11
representative 800 kb regions of association across the genome. The SNPs with the most
significant p-value in each region were selected as index SNPs (see table 6).
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Table 6: Top Regions in Obese Individuals (Method 1)
Index SNPs from 11 genomic regions associated with hsCRP levels in obese European-Americans. Only the top SNP,
rs4420638, reached the set genome wide significance level of 5.00*10-8. SNPs with function listed as unknown have nearby
gene(s) reported. Those with function listed as intron have the gene they are in indicated with an (i) and any nearby gene
reported (if relevant).
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The most significant region of association is represented by the SNP rs4420638 (pvalue 1.86*10-9) on chromosome 19 (figure 2). This SNP has a β value of 0.22. In the top
36 significantly associated SNPs, only the top four are in this region. rs6857 (p-value =
1.31*10-8) is located in the poliovirus receptor-related 2 (PVRL2) gene. The third most
significant SNP (p-value = 3.84*10-7) is rs2075650 and it is contained in the TOMM40
gene. The SNP rs439401 (p-value = 4.71*10-7) in LOC100129500 (also the gene in which
rs4420638 is located) is the fourth most significantly hsCRP associated SNP.
23 SNPs located in chromosome 1 in the region containing the CRP gene are
moderately associated with hsCRP levels in the 2,411 obese individuals. This region is
represented in figure 2 with rs12068753 as the index SNP (p-value = 8.02*10-7). With
addition of each A allele at the rs12068753 locus, hsCRP levels increase by 0.27.
rs11265260, the top SNP in this region in lean individuals, is associated with hsCRP levels
in obese individuals with a significance level of 7.15*10-6.
The other 9 SNPs in the top 36 were the only SNPs in their respective regions (see
figure 2) found to be associated with hsCRP levels in obese individuals. These SNPs were
found in chromosome 16 (rs13330968, p-value = 1.49*10-6), chromosome 7 (rs4278077, pvalue = 6.19*10-6), chromosome 9 (rs2808988, p-value = 6.70*10-7 and rs7019284, p-value
= 9.95*10-6), chromosome 12 (rs5008004, p-value = 8.49*10-6), chromosome 13
(rs17086609, p-value = 8.56*10-6), chromosome 11 (rs629882, p-value = 8.89*10-6),
chromosome 14 (rs4903731, p-value = 9.16*10-6), and chromosome 19 (rs10408037, pvalue = 9.94*10-6). Genes in these regions include Bardet-Biedl syndrome 9 (BBS9),
leucine rich repeat and Ig domain containing 2 (LINGO2). PDZ domain containing ring
finger 4 (PDZRN4), vascular endothelial growth factor receptor 1 (FLT1), CMP-N38

acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase (ST3GAL4), neurexin 3
(NRXN3), Kallikrein-5 (KLK5), and family with sequence similarity 75, member A6
(FAM75A6).
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Figure 4: Plots of Top Regions in Lean Individuals

Regional plots of 11 loci showing moderate genome-wide significant association with hsCRP levels in European-American obese individuals. This plot
shows the four most significant regions (refer to table 6). Each region’s rank is at the bottom right corner of each plot. In each plot, the top SNP is
designated by a purple diamond. – log10 p-values are on the y-axis and SNP genomic positions are on the x-axis. Genes which flank the 800 kb regions
are reported under the x-axis. The estimated rates of recombination are marked in blue. Each SNP is colored to show linkage disequilibrium (LD) with the
top SNP.
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Figure 2 continued: Regional plots of 11 loci showing moderate genome-wide significant association with hsCRP levels in European-American obese
individuals. This plot shows the 5th through 8th most significant regions (refer to table 6). Each region’s rank is at the bottom right corner of each plot. In
each plot, the top SNP is designated by a purple diamond. – log10 p-values are on the y-axis and SNP genomic positions are on the x-axis. Genes which
flank the 800 kb regions are reported under the x-axis. The estimated rates of recombination are marked in blue. Each SNP is colored to show linkage
disequilibrium (LD) with the top SNP.
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Figure 2 continued: Regional plots of 11 loci showing moderate genome-wide significant association with hsCRP levels in European American obese
individuals. This plot shows the 9th through 11th most significant regions (refer to table 6). Each region’s rank is at the bottom right corner of each plot.
In each plot, the top SNP is designated by a purple diamond. – log10 p-values are on the y-axis and SNP genomic positions are on the x-axis. Genes
which flank the 800 kb regions are reported under the x-axis. The estimated rates of recombination are marked in blue. Each SNP is colored to show
linkage disequilibrium (LD) with the top SNP.
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Comparison of GWA Results between Lean and Obese Individuals
The first aim of this thesis was to investigate which SNPs interact with BMI to
influence the outcome of hsCRP levels. The first method used to do this was to compare the
SNP association results from the separate GWA analyses done in lean and obese individuals
(results above). Index SNPs from the 16 regions of significant association with hsCRP
levels in lean individuals and the 11 regions of significant association with hsCRP levels in
obese individuals were used in this analysis. Two of those regions were similar in both the
lean and obese individuals leaving 25 unique regions.
To compare the effects of each region between BMI strata, the β value for each index
SNP in lean individuals was compared to the β value for each index SNP in obese
individuals using a t-statistic:
(bo – bl) / √(seo2 + sel2 - 2*corr(bo,bl)*seo*sel)
The Pearson correlation between the lean and obese β estimates for all SNPs in the GWAS
was calculated to be 0.0305. Because of the large sample size (2,083 lean individuals, 2,411
obese individuals), the t-test is treated as a z-test. The p-value for significance was set at
0.05 divided by the number of independent SNPs being investigated (0.05/25 = 2.00*10-3).
This 2-sided p-value corresponds to the z-test statistic of ± 3.09. In any SNP comparison
with a test statistic greater than 3.09 and less than -3.09 the null hypothesis is rejected and
that SNP can be considered to differ significantly between obesity strata in their influence of
hsCRP levels. Table 7 provides information on the 16 regions which were found to be
significant by this test.
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Of the 16 regions found to differ significantly in their effects on lean and obese
individuals, the most significant was on chromosome 2. The index SNP was rs12713007 and had a
p-value of 2.00*10-6. The region was identified in the GWA performed in the lean subsample. It
contained 18 SNPs which all had moderately significant (10-6 < 10-7) p-values of association. None
of these SNPs were in a known gene, however, all 18 SNPs are contained in the 400 kb region
between the genes FBXO11 and FOXN2.
The 15 other regions found to differ significantly between lean and obese individuals had
index SNPs with p-values ranging between 1.88*10-3 and 6.00*10-6. These include regions located
in or near KCNAB1 (rs13093806, p-value = 6.00*10-6) on chromosome 3, TGFB2

(rs4335431, p-value = 3.00*10-5) on chromosome 1, ITGB1 and NRP1 (rs12260720, p-value
= 3.20*10-5) on chromosome 10, PTGR1 and ZNF483 (rs7026971, p-value = 5.00*10-5) on
chromosome 9, GJA5 and GJA8 (rs12568235, p-value = 5.80*10-5) on chromosome 1,
NRXN3 (rs4903731, p-value = 9.40*10-5) on chromosome 14, ZNF536 (rs12463210, pvalue = 1.22*10-4) on chromosome 19, EPHA8 (rs663002, p-value = 2.30*10-4) on
chromosome 1, PCDH7 (rs7662351, p-value = 4.43*10-4) on chromosome 4, IFT172 and
GCKR (rs2272417, p-value = 4.68*10-4) on chromosome 2, MANEA (rs4448101, p-value =
5.06*10-4) on chromosome 6, SLCO1B1 (rs10841753, p-value = 6.08*10-4) on chromosome
12, PDZRN4 (rs5008004, p-value = 7.16*10-4) on chromosome 12, KLK5 (rs10408037, pvalue = 7.76*10-4) on chromosome 19, and FLT1 (rs17086609, p-value = 1.88*10-3) on
chromosome 13.
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Table 7: Top Regions Identified by Method 1 Comparison
Information on 16 regions which represent the regions found through comparison of obese strata-specific β values to have
significantly different effects on hsCRP levels. SNPs with function listed as unknown have nearby gene(s) reported. Those

with function listed as intron have the gene they are in indicated with an (i) and any nearby gene reported (if relevant).
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3.3 AIM 1: Method 2
The second series of analyses used a SNP by BMI interaction term to investigate the
pairwise interaction between the 2,543,887 genetic polymorphisms and BMI in all
genotyped individuals (i.e. not a priori stratified for obesity status).. The linear regression
was adjusted for age, sex and SNP, and an additive genetic model was assumed. 40 SNPs
reached the set significance level of less than 10-5 (see table 8). These 40 SNPs were
contained in 11 genomic regions.
The index SNP with the most significant interaction term (p-value = 6.710*10-7) was
found on chromosome 5 in the gene encoding transcription factor TFIIIB component B
homolog (BDP1). The index SNPs in the remaining 10 regions found to interact
significantly with BMI to influence hsCRP levels include: rs4265829 (p-value = 1.980*10-6)
on chromosome 8 near LOC100132891, rs1481852 (p-value = 2.310*10-6) on chromosome
5 in the gene cadherin 9 type 2 (CDH9), rs7476844 (p-value = 3.32*10-6) on chromosome
10 in no known gene, rs12568235 (p-value = 3.450*10-6) near GJA5 and GJA8 on
chromosome 1, rs12713007 (p-value = 5.11*10-6) near FXO11 and FOXN2 on chromosome
2, rs1955377, p-value = 6.200*10-6 on chromosome 3, rs1793615 (p-value = 8.330*10-6)
near the neurotrimin gene (NTM) on chromosome 11, rs11708430 (p-value = 8.63*10-6) on
chromosome 3 in no known gene, rs11136787 (p-value = 9.190*10-6) in CUB and sushi
domain-containing protein 1 (CSMD1) on chromosome 8, and rs9386702 (p-value =
9.88*10-6) in osteopetrosis associated transmembrane protein 1 (OSTM1) on chromosome 6.
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Table 8: Top Regions found to Interact with BMI (Method 2)
Index SNPs of the 11 regions found through a GWA analysis in the ARIC cohort to interact significantly (p-value < 10-5)
with BMI to influence hsCRP levels in this sample of European-Americans. SNPs with function listed as unknown have
nearby gene(s) reported. Those with function listed as intron have the gene they are in indicated with an (i) and any nearby
gene reported (if relevant).
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3.4 Exploratory Aim 2
To identify genomic regions which interact with BMI to influence hsCRP levels in
the subsample of European-Americans used in this thesis, the results from the two methods
used in the first aim were compared. Two regions, defined by the index SNPs, on
chromosome 2 and chromosome 1 were identified to be significant or suggestive by both
methods. Table 9 contains information about these regions. The region containing the SNP
on chromosome 2 was found near the genes FXO11 and FOXN2, and the region containing
the SNP on chromosome 1 was found near the genes GJA5 and GJA8 (see figure 1 above to
view regions).
The region on chromosome 2, found near the genes FXO11 and FOXN2, contained
18 SNPs (including the index SNP, rs12713007) which were all found to be moderately
associated (p-values between 4.87*10-6 and 9.65*10-6) with hsCRP levels in lean
individuals. Seven of these SNPs had negative β values falling around -0.1550. The other
11 had positive β values falling in a similar range. The β-values of these SNPs in obese
individuals were not found to be significant, but were discovered to have opposite effects
(negative instead of positive β-values and vice versa) with magnitudes between 0.04 and
0.05. The differences between the β-values in lean and obese individuals for each SNP were
significantly different from zero (p-values between 1.57*10-6 and 2.00*10-6). The analysis
performed on the un-stratified European-American subsample also showed each of these 18
SNPs to interact significantly (p-values between 7.88*10-6 and 5.11*10-6) with BMI. The βvalues for each interaction were all found to have a magnitude of around 0.01 (7 SNPs with
positive values and 11 with negative values). The 7 SNPs with positive β-values of
interaction were the same SNPs with positive β-values in the association analysis using only
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obese individuals. The index SNP, rs12568235, on chromosome 1 was in a region
containing the genes GJA5 and GJA8.
Through comparison of the two methods it was the only SNP in this region found to
interact with BMI. It was significantly associated with hsCRP levels in lean individuals
with a β value of 2.28. The SNP’s association with hsCRP levels in obese individuals was
not significant, but had an opposite effect with a β value of -0.16. Comparison of these two
β values was significant (p-value = 1.80*10-5). The un-stratified interaction analysis was
also significant (p-value of 3.45*10-6) with a β value of -0.20.
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Table 9: Two Regions which Possibly Interact with BMI (Exploratory Aim 2)
Information about the 2 regions found to interact with BMI to influence hsCRP levels in European-Americans. They were
identified through the comparison of two separate methods used to investigate the interaction. This table contains the β values and
corresponding p-values from the stratified association analyses (in lean and obese individuals), the t-statistics and p-values from the
comparison of the results from these association analyses, and the β values and corresponding p-values from the non-stratified
interaction analysis.
.
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CHAPTER 4: DISCUSSION
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4.1 Identifying Genes that Possibly Interact with BMI to Influence hsCRP Levels
C-Reactive Protein is a biomarker for inflammation whose increased plasma levels are
observed to accompany atherosclerotic coronary heart disease (16, 17, 18, 19, 20, 21, 23, 24,
25). It is produced in hepatocytes and secreted by the liver and CRP production is regulated
by cytokines such as IL-6 and TNF-α (6, 8). In addition to being a biomarker of CHD,
increased levels of CRP may also play a key role in the development of CHD (14, 15, 20).
Furthermore, CRP levels have been observed to be correlated with body mass index (20, 34,
36), a common risk factor known to increase CHD risk (20). CRP also has a recognized
genetic component. Multiple GWAS have identified multiple genetic polymorphisms which
influence CRP levels. SNPs implicated in such studies have been found in or near genes of
interest including: CRP, APOE, APOC, IL-6, HNF1A, LEPR, and GCKR (39, 40, 41, 42,
43). Because of the genetic influence on CRP levels in conjunction with the link between
BMI and CRP levels, we undertook and presented the results of a series of analyses
designed to identify loci which interact with BMI to influence CRP levels in a subsample of
European-Americans in the ARIC cohort. By using and then synthesizing the results from
two statistical methods used to investigate this interaction, we identified three genes, GJA5,
GJA8 and FBXO11, which interact with BMI to influence hsCRP levels. Because there have
been previous GWA studies of CRP with much larger sample sizes and because those genes
with main effects on CRP have been adequately discussed, this discussion will limit itself to
only those genes with suggestive or significant evidence for an interaction with BMI as they
combine to influence of hsCRP levels.
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Method 1: Stratified analysis
By comparing our stratified analyses, we found 16 regions (see table 7) to have
significantly distinct effects (p-value < 2.00*10-3) on hsCRP levels between the two obesity
strata (lean and obese). Fifteen of them were not previously reported in CRP GWA studies,
and only one region, containing the GCKR gene, was previously reported as being
associated with CRP levels in non-stratified CRP GWA studies (39, 43).
In addition to the region containing GCKR, regions on chromosome 1 containing the
TGF-β2 gene, on chromosome 10 containing ITGB1 and NRP1, on chromosome 2
containing FBXO11, on chromosome 1 containing GJA5 and GJA8, and on chromosome 13
containing FLT1 were of particular interest to us, because of their known affiliation with
CRP or the inflammatory process. TGF-β has been identified as a cytokine having a
regulatory effect on CRP production (8). ITGB1 is an integrin which is a protein known to
participate in the immune response (52). NRP1 has been suggested as playing a role in
inflammation via the vascular endothelial growth factor receptor (VEGF) signaling pathway
(53). The VEGF-A protein and TGF-β were both found to increase during atherogenesis
(54). It has been reported that the vascular endothelial growth factor receptor 1, a tyrosinekinase found in monocytes and encoded by FLT1, in its soluble form (sFLT1) is also
positively correlated with VEGF. After binding to VEGF, it inhibits VEGF from binding to
endothelial cells and, in turn, prevents cell migration. In the same study, VEGF was also
found to be positively correlated with CRP levels (55). We will discuss FBXO11, GJA5,
and GJA8 in more detail in the following sections of the discussion. The loci containing
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TGF-β2, ITGB1 and NRP1, FBXO11, and GJA5 and GJA8 were all associated significantly
with hsCRP levels specifically in the lean subsample, this suggests their effect is greatest in
individuals with a lower BMI. FLT1 was associated was significantly associated with
hsCRP levels in only in the obese subsample.
The genes in regions we found to have significantly different effects on hsCRP levels
and which have no a priori obvious relationship to CRP include: FOXN2, KCNAB1,
PTGR1, ZNF483, NRXN3, ZNF536, EPHA8, PCDH7, IFT172, MANEA, SLCO1B1,
PDZRN4, and KLK5. Additional stratified analyses should be done to replicate or validate
these findings in well-powered independent samples.

Method 2: Interaction analysis
Using the second method, a formal interaction modeling strategy, to accomplish the
overall research objective, we observed 11 genomic regions (see table 8) to significantly
interact (p-value < 10-5) with BMI to influence hsCRP levels in the combined EuropeanAmerican sample. No SNP or gene reported as being associated with CRP levels in any
published CRP GWAS was found to have an interactive effect with BMI on hsCRP levels in
this thesis. Through literature searches we concluded that only two regions identified
through this interaction analysis were biologically implicated in CRP production or
regulation. These are the regions containing GJA5 and GJA8 (chromosome 1), and
FBXO11 (chromosome 2). The genes in regions found to interact with BMI to influence
hsCRP levels in this analysis which have no a priori obvious link to CRP are BDP1,
LOC100132891, CDH9, FOXN2, NTM, CSMD1, and OSTM1.
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Comparison of Methods
The two regions containing GJA5/GJA8 and FBXO11 provided consistent and
statistically significant results using both methods employed in this thesis. Using the
criterion of consistency between the two methods, these are the only two regions found to
interact with BMI to influence hsCRP levels in this thesis. These statistically significant
results do not necessarily mean that there is biologic interaction between the index SNPs
(rs12713007 and rs12568235) and BMI causing a change in hsCRP levels. The results may
simply imply that these SNPs are near or in linkage disequilibrium (LD) with the
unmeasured or unknown causal variant or gene in their respective regions that interacts with
BMI to influence hsCRP levels. For this reason, genes located near these two index SNPs
were carefully considered and researched for functional relevance to CRP.

4.2 GJA8 and GJA5
In analytic strategies presented above, rs12568235 on chromosome 1 was the only
SNP in a 800 kb region found to be statistically significant. The closest two genes, GJA5
and GJA8, located on either side of the SNP (see figure 1, region 13) were considered as loci
having possible interactive effects with BMI on hsCRP levels.
GJA5 codes for the cardiac gap junction protein connexin 40 whose composition of
intercellular channel arrays allows low molecular weight materials to move from cell to cell.
It is expressed specifically in atrial myocytes, and its function is to mediate “the coordinated
electrical activation of the atria” (56, 57). One study investigating heterozygous missense
mutations in GJA5 concluded that such mutations may inhibit assembly of the gap junctions
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or damage electrical coupling. These impairments of function could predispose individuals
with such mutations to idiopathic atrial fibrillation (AF) (57). AF, which affects 2.3 million
people in the US, is associated with increased risks for clot formation and stroke ((58). It
has also been reported that traditional risk factors for CHD, such as CRP, are predictive of
AF (59, 60). It is not known whether AF directly activates inflammation or if pre-existing
inflammation and its accompanying elevated CRP levels promote AF (59, 61-63). Future
studies should investigate the association between CRP and AF to speculate on which
process is biologically most probable.
Although GJA8, a gene encoding for connexin 50 (64), has not been previously
reported to be associated with CRP levels, it is known that variations in GJA8 have been
associated with a number of cataract syndromes (65, 66) including congenital inherited
cataracts (64). GJA8 is critical in the transport of “second messengers, metabolites, ions and
water between the lens epithelium and the central lens nucleus” (67). Several studies have
suggested and found that genetic polymorphisms involved in congenital cataracts, such as
those in GJA8, also play a role in age-related cataracts (64, 68, 69, 70). Age-related
cataract, a multifactorial disease making up 80% of all cataracts world-wide (71), is the
principal source of visual impairment and blindness (72). In addition to having a genetic
component, age-related cataracts are also environmentally influenced by high BMI (73) and
inflammation (74, 75). Because of its association with inflammation, several studies
investigated the relationship between age-related cataract and CRP levels (74, 76).
Schaumberg et al studied CRP’s relationship with the risk for future age-related cataract in
834 men and found an association in apparently healthy men (those with CRP levels ≥ 6.17
mg/l had a three-fold elevated risk of age-related cataract) (74).

56

The results of this thesis indicate that GJA5 and GJA8 possibly interact with BMI to
influence hsCRP levels in European-Americans. In conjunction with the preceding
information the results suggest that GJA5 and GJA8 may interact with BMI to influence
hsCRP levels through the inflammatory processes involved in AF and age-related cataracts
respectively.

4.3 FBXO11
rs12713007 and 18 other significantly or suggestive SNPs on chromosome 2 are
found in a ~400 kb region located upstream of FBXO11 and downstream of FOXN2.
FOXN2, is a transcriptional regulator of the T-cell leukemia virus long terminal repeat in
humans (77), was found to have no obvious connection to CRP. In two separate studies,
FBXO11 has been associated with a common childhood disease called otitis media (OM).
OM is characterized by inflammation of the middle ear arising with infection (78, 79).
Through use of Jeff, a mouse mutant model for OM, FBXO11 was identified as an
underlying susceptibility gene (79, 80). In humans, the association between FBX011 and
OM has been replicated in two separate studies of Western Australian children (78). In
functional studies, FBXO11 was found to play a role in the regulation of the TGF-β pathway
(79), possibly through neddylation and stabilization of p53, a cofactor of pospho-Smad2
(pSmad2)(81). Stabilization of p53 is mandatory to reduce accumulation of pSmad2 in the
nucleus of epithelial cells (79, 82). The partnering of p53 and pSmad2 activates TGF- β
target genes (82). The TGF-β pathway and release of the TGF- β protein during the acute
stage of inflammation (83, 84) is known to play a regulatory role in cytokine-driven CRP
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production (8). This information in addition to the results of this thesis suggests that
FBXO11 interacts with BMI to influence hsCRP levels through the TGF-β pathway.

4.4 Conclusions and Future Studies
The primary objective of this thesis was to identify genes which interact with BMI to
influence hsCRP levels in European-Americans in the ARIC cohort. Evidence for such an
interaction with the genes GJA5, GJA8 and FBXO11 include: discovery through two
separate statistical analysis strategies of rs12568235 and rs12713007 to interact significantly
with BMI to affect hsCRP levels ; the close proximity of GJA5 and GJA8 to rs12568235
and of FBXO11 to rs12713007; and the biological link between mutations in these two
genes and CRP levels. We speculate that atrial fibrillation (AF), age-related cataract and the
TGF-β pathway may be biological processes influenced by the interaction of GJA5, GJA8
and FBXO11, respectively, with BMI to cause changes in hsCRP levels. If these results can
be reproduced in other studies and populations, the next step could be to investigate in
further detail how CRP levels and these biological processes affected each other. Future
studies should focus on the influence of gene x bmi interaction on AF, age-related cataracts
and the TGF-β pathway.
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APPENDIX
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Supplementary Table 1: Top 145 SNPs associated with hsCRP levels in EuropeanAmerican lean individuals. SNPs with function listed as unknown have nearby gene(s)
reported. Those with function listed as intron have the gene they are in indicated with an (i)
and any nearby gene reported (if relevant). The SNP highlighted in pink is the index SNP
in its respective region.
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Supplementary Table 1 continued: Top 145 SNPs associated with hsCRP levels in
European-American lean individuals. SNPs with function listed as unknown have nearby
gene(s) reported. Those with function listed as intron have the gene they are in indicated
with an (i) and any nearby gene reported (if relevant). The SNP highlighted in pink is the
index SNP in its respective region.
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Supplementary Table 1 continued: Top 145 SNPs associated with hsCRP levels in
European-American lean individuals. SNPs with function listed as unknown have nearby
gene(s) reported. Those with function listed as intron have the gene they are in indicated
with an (i) and any nearby gene reported (if relevant). The SNP highlighted in pink is the
index SNP in its respective region.
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Supplementary Table 2: Top 36 SNPs associated with hsCRP levels in EuropeanAmerican lean individuals. SNPs with function listed as unknown have nearby gene(s)
reported. Those with function listed as intron have the gene they are in indicated with an (i)
and any nearby gene reported (if relevant). The SNP highlighted in pink is the index SNP
in its respective region.
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